Table 1. Antibacterial spectrum SBT ABPC ABPC CPZ : sulbactamiampicillin : ampicillin : cefoperazone

Similar documents
CHEMOTHERAPY

CHEMOTHERAPY

Fig.2. Sensitivity distribution of clinical isolates of S. epidermidis (24 strains, 106 CFU/ml) Staphylococcus aureus Staphylococcus epider- midis Ent

Staphylococcus sp. K.pneumoniae P.mirabilis C.freundii E. cloacae Serratia sp. P. aeruginosa ml, Enterococcus avium >100ƒÊg/ml


Key words : 7432-S, Oral cephem, Urinary tract infection Fig. 1. Chemical structure of 7432-S.

epidermidis, Enterococcus faecalis, Enterococcus Klebsiella pneumoniae, Proteus mirabilis, indolepositive Proteus spp., Enterobacter spp., Serratia

CHEMOTHERAPY


CHEMOTHERAPY Table 1 Clinical effect of Sultamicillin

VOL.42 S-1 methicillin-susceptible Staphylococcus aureus (MSSA), Staphylococcus epidermidis, Enterococcus faecalis, Escherichia coli, Klebsiella pneum

Fig. 1 Chemical structure of DL-8280

VOL.35 S-2 CHEMOTHERAPY Table 1 Sex and age distribution Table 2 Applications of treatment with carumonam Table 3 Concentration of carumonam in human

CHEMOTHERAPY JUN Citrobacter freundii 27, Enterobacter aerogenes 26, Enterobacter cloacae 27, Proteus rettgeri 7, Proteus inconstans 20, Proteus

1272 CHEMOTHERAPY MAR. 1975

CHEMOTHERAPY FEB Table 1. Activity of cefpirome and others against clinical isolates

VOL. 43 NO. 4


CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study

CHEMOTHERAPY aureus 0.10, Enterococcus faecalis 3.13, Escherichia coli 0.20, Klebsiella pneumoniae, Enterobacter spp., Serratia marcescens 0.78, Prote

VOL.32 S-7 CHEMOTHERAPY Table 1 MIC of standard strains of CTRX Fig. 2 Cumulative curves of MIC S. aureus (26 strains )


VOL. 40 S- 1 Table 1. Susceptibility of methicillin-resistant Staphylococcus aureus to meropenem Table 2. Coagulase typing of methicillin-resistant St

CHEMOTHERAPY Fig. 1 Chemical structure of CXM-AX

Fig. 1 Chemical structure of KW-1070

coccus aureus Corynebacterium sp, Haemophilus parainfluenzae Klebsiella pneumoniae Pseudornonas aeruginosa Pseudomonas sp., Xanthomonas maltophilia, F

Clostridium difficile ciprofloxacin, ofloxacin, norfloxacin Bifidobacterium Lactobacillus Lactobacillus Bacteroides fragilis B. fragilis C. difficile


VOL.42 S-1

CHEMOTHERAPY DEC (NFLX), ofloxacin (OFLX), ciprofloxacin (CPFX) Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Enterococcus faecali


CHEMOTHERAPY Table 1 Urinary excretion of mezlocillin Fig. 4 Urinary excretion of mezlocillin Fig. 3 Blood levels of mezlocillin

CHEMOTHERAPY NOV S. aureus, S. epidermidis, E. coli, K. pgeumoniae, E. cloacae, S. marcescens, P. mirabilis, Proteus, P. aeruginosa Inoculum siz

THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec DNA 2, , % 1.65% 1.17% 90% 9 Escherichia coli -


CHEMOTHERAPY


VOL.47 NO.5 Table 1. Susceptibility distribution of Ĉ- lactams against clinical isolates of MRSA MRSA: rnethicillin- resistant Staphylococcus aureus

Table 1 Classification of female patients with vesical irritating symptom by their signs : Urinary pain with or without other vesical irritability. s

Table 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates

Table1MIC of BAY o 9867 against standard strains

Mueller-Hinton broth), Streptococcus pneumoniae (S. pneumoniae), Streptococcus faecalis (S. faecalis)

988 CHEMOTHERAPY NOV. 1971


Fig.1 Chemical structure of BAY o 9867




CHEMOTHERAPY Proteus mirabilis GN-79 Escherichia coli No. 35 Proteus vulgaris GN-76 Pseudomonas aeruginosa No. 11 Escherichia coli ML-1410 RGN-823 Kle

Hisao Takayasu Department of Urology, Faculty of Medicine, University of Tokyo Masaaki Ohkoshi Department of Urology, Tokai University School of Medic


Fig. 1 Chemical structure of TE-031 Code number: TE-031 Chemical name: (-) (3R, 4S, 5S, 6R, 7R, 9R, 11R, 12R, 13S, 14R)-4-[(2, 6-dideoxy-3-C-methyl-3-

CHEMOTHERAPY JUNE 1987 Table1 Media used *BHIB, brain heart infusion broth (Difco); /3 -NAD, S -nicotinamidoadeninedinucleotide (Sigma Chemical Co.);

CHEMOTHERAPY JUNE 1986

VOL. 23 NO. 3 CHEMOTHERAPY 1067 Table 2 Sensitivity of gram positive cocci isolated from various diagnostic materials Table 3 Sensitivity of gram nega

CHEMOTHERAPY DEC Table 1 Antibacterial spectra of T-1982, CTT, CMZ, CTX, CPZ and CEZ 106 CFU/ml Note: P; Peptococcus, S; Streptococcus, G; Gaffk

pneumoniae 30, C. freundii 32, E. aerogenes 27, E. cloacae 32, P. mirabilis 31, P. vulgaris 34, M. morganii 32, S. marcescens 31, H. influenzae 27, P.

VOL.30 S-1 CHEMOTHERAPY Table 1 Antibacterial activity of CTT against standard strains Table 2 Antibacterial activity of CTT against standard strains



CHEMO THE RAPY OCT. 1994

Fig. 1 Chemical structure of norfioxacin (AM-715)


Fig. 1 Clinical findings and extent of inflammation area in female urethrocystitis Fig. 2 Classification and distribution of female patients with blad

THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec LVFX 100 mg 3 / mg 2 / LVFX PK PD mg mg 1 1 AUC/MIC

VOL.27 S-5 CHEMOTHERAPY Table 1 Clinical evaluations of cefamandole on UTI (1) Benign prostatic hypertrophy (2) Transurethral resection of bladder tum

CHEMOTHERAPY FEB Table 1 Background of volunteers


Feb THE JAPANESE JOURNAL OF ANTIBIOTICS Tebipenem pivoxil 1 1, Meiji Seika 2 Meiji Seika G 3 Meiji Seika Tebipen

THE JAPANESE JOURNAL OF ANTIBIOTICS 68 3 June 2015 Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis % 2 S. pneumon


CHEMOTHERAPY DEC phvlococcus aureus Staphylococcus Enterococcus faecalis Escherichia Klebsiella pneumoniae Serratia marcescens Pseudomonas cepac

Dec. THE JAPANESE JOURNAL OF ANTIBIOTICS XXXVII (45)

CHEMOTHERAPY APR Fig. 2 The inactivation of aminoglycoside antibiotics by PC-904 Fig. 3 Serum concentration of PC-904 (1) Fig. 4 Urinary recover

VOL.48 NO.7 lase negative staphylococci, Escherichia coli, Klebsiella spp., Citrobacter freundii, Enterobacter spp., indole-positive Proteus, Serratia

CHEMOTHERAPY Methicillin-resistant S.aureus(MRSA) coccus epidermidis 105 Streptococcus pyogenes E.faecali senterococcus avium Enterococcus faecium Str

CHEMOTHERAPY MAY. 1988

日本化学療法学会雑誌第65巻第4号

CHEMOTHERAPY OCT Fig. 1 Chemical structure of CVA-K

THE JAPANESE JOURNAL OF ANTIBIOTICS 48-8 Enterococcus avium 5Š, Corynebacterium xerosis 10Š, Corynebacterium pseudodiphtheriticum 10Š, Corynebacterium









Key words: E. coli O 157: H7, fosfomycin, verotoxin, mouse infection

CHEMOTHERAPY APRIL 1992 Acinetobacter calcoaceticus Staphylococcus aureus, Escherichia coli P. aeruginosa E. eoli, Klebsiella pneumoniae Serratia marc



Title 外傷性脊髄損傷患者の泌尿器科学的研究第 3 報 : 上部尿路のレ線学的研究並びに腎機能について Author(s) 伊藤, 順勉 Citation 泌尿器科紀要 (1965), 11(4): Issue Date URL

日本化学療法学会雑誌第59巻第5号

VOL.27 CHEMOT S-1 HERAPY 185 に感 性 を示 して い たが,臨 床 的 に は無 効 で あ った 本 症 る 細 菌学 的 に も検 討 した が,起 炎菌 と考 え られ る細 菌 を 例 で は 基礎 疾 患 と して縦 隔 洞腫 瘍 が あ り,既 に 副 腎


2108 CHEMOTHERAPY SEPT Table 1 Antimicrobial spectrum Fig. 1

日本化学療法学会雑誌第61巻第6号

VOL. 34 S-2 CHEMOTH8RAPY 913

VOL. 21 NO. 2 CHEMOTHERAPY 395

Transcription:

Table 1. Antibacterial spectrum SBT ABPC ABPC CPZ : sulbactamiampicillin : ampicillin : cefoperazone

(inoculum size= 106 CFU/ml) (Ĉ-lactamase producer : 2 strains) Fig. 1. Sensitivity distribution of S. aureus isolated from urinary tract (inoculum size= 106 CFU/ml) (Ĉ-lactamase producer : 4 strains) Fig. 2. Sensitivity distribution of S. epidermidis isolated from urinary tract

(inoculum size=106 CFU/ml) Fig. 3. Sensitivity distribution of E. coli isolated from urinary tract (inoculum size=106 CFU/ml) Fig. 4. Sensitivity distribution of C. freundii isolated from urinary tract

Fig. 5. Sensitivity distribution of K. pneumoniae isolated from urinary tract Fig. 6. Sensitivity distribution of E. cloacae isolated from urinary tract

Table 3. Overall clinical efficacy of sulbactamiampicillin in complicated UTI 1.5 g ~ 2/day treatment Table 4. Overall clinical efficacy of sulbactam ampicillin classified by type of infection

Table 5. Bacteriological response to sulbactam Eampicillin in complicated UTI : regardless of bacterial count : glucose non-fermenting Gram-negative rod Table 6. Strains* appearing after sulbactam Eampicillin treatment in complicated UTI

Table 7. Incidence of clinical adverse reactions must be discontinued and some treatment for the adverse reaction is needed can be continued, although some treatment for the adverse reaction is needed the adverse reaction is needed Table 8. Changes in laboratory test results

1) ENGLISH A R, RETSEMA J A, GIRARD A E, LYNCH J E, BARTH W E: CP-45, 899, a beta-lactamase inhibitor that extends the antibacterial spectrum of beta-lactams : initial bacteriological characterization. Antimicrob Agents Chemother 14 : 414 `419, 1978 2) PITTS N E, KINIRSCH A K, LEES L, MCBRIDE T J, MEHTA D J : Ĉ-lactamase blocking agents. Experience with sulbactam E ampicillin, 14th ICC, beta-lactamase blocking agents : Proceeding 25-34, 1985 7) RETSEMA J A, ENGLISH A R, GIRARD A E, ANDERSON M, BRENNAN L, CIMOCHOWSKI C, FAIELLA J, HERBERT C: Sulbactam and ampicil. lin : Synergistic antibacterial activity against hospital isolates of Enterobacleriaceae, methicillin-resistant Staphylococcus, and anaer. obes. proceeding of the 13th ICC part 23 : 1 `5, 1983 ANTIMICROBIAL ACTIVITY AND CLINICAL EFFICACY OF SULBACTAM AMPICILLIN IN URINARY TRACT INFECTIONS MASAYOSHI YAMAHA, SATOSHI ISHIHARA, HIDER HAYASHI, IKUO SHINODA, HARU KATOH, AKIHIRO SAITOH, TOSHIMI TAKEUCHI, MINORU KANEMATSU and YOSHIHITO BAN Department of Urology, School of Medicine, Gifu University 40 Tsukasa-machi, Gifu 500, Japan HISAO KOMEDA, YASUO SHIMIZU and YUKIMICHI KAWADA Department of Urology, Fukui Medical School We studied the antimicrobial activity against urinary bacteria and clinical efficacy in urinary tract infections of sulbactam Eampicillin (SBT EABPC), a new combination drug. This drug consists of sulbactam (SBT), a The in vitro activity of SBT EABPC against Gram-positive bacteria was nearly the same as that of ABPC. SBT-ABPC, however, was more active against Gram-negative bacteria than was ABPC. One patient with acute uncomplicated pyelonephritis and 22 with complicated urinary tract infection were given 1.5g of SBT E ABPC twice a day for 5 days by intravenous route. Clinical efficacy in the patient with acute pyelonephritis was evaluated as excellent. In 17 of the 22 patients with complicated urinary tract infection, it was evaluated by the criteria of the Japanese UTI Committee; excellent and moderate responses were obtained in 82 %. Of 21 strains isolated from patients with complicated urinary tract infections, 19 (90%), including 6 high Clinical adverese reactions were evaluated in 23 patients. Skin rash was observed in 2, but spontaneously resolved after treatment. From the results obtained in this study, SST. ABPC was considered to be effective in the treatment of urinary tract infections, especially those due to Ĉ-lactamase-producing organisms.

2024 © docsplayer.net プライバシー | 利用規約 | フィードバック